PharmVar GeneFocus: CYP2A6
Clinical Pharmacology & Therapeutics2024Vol. 116(4), pp. 948–962
Citations Over TimeTop 10% of 2024 papers
Alec W. R. Langlois, Meghan J. Chenoweth, David Twesigomwe, Giada Scantamburlo, Michelle Whirl‐Carrillo, Katrin Sangkuhl, Teri E. Klein, Charity Nofziger, Rachel F. Tyndale, Andrea Gaedigk
Abstract
The Pharmacogene Variation Consortium (PharmVar) provides nomenclature for the human CYP2A gene locus containing the highly polymorphic CYP2A6 gene. CYP2A6 plays a role in the metabolism of nicotine and various drugs. Thus, genetic variation can substantially contribute to the function of this enzyme and associated efficacy and safety. This GeneFocus provides an overview of the clinical significance of CYP2A6, including its genetic variation and function. We also highlight and discuss caveats in the identification and characterization of allelic variation of this complex pharmacogene, a prerequisite for accurate genotype determination and prediction of phenotype status.
Related Papers
- → The p.Arg377Trp variant in ACTL6A underlines a recognizable BAF‐opathy phenotype(2020)5 cited
- → CMT4D (NDRG1 mutation): genotype–phenotype correlations(2013)13 cited
- One gene, many phenotypes(2009)
- → New clinical features of Fanconi anemia(2010)
- → Standardized phenotype documentation, documentation of genotype phenotype correlations(2021)